- Professor Masakazu Toi, M.D. Ph.D
- Kyoto University Graduate School of Medicine, Kyoto, Japan.
Website | E-mail
Special Issue Introduction
Triple negative breast cancer (TNBC) having hormone receptor negative and HER2 negative phenotype is a disease consisting of heterogeneous populations. Biological properties differ significantly among these subpopulations, so that multiple treatment strategies and a variety of approaches would be required to overcome the disease. In common practice, chemotherapies, such as anthracyclines, microtubules inhibitors and oral fluoropyrimidines, are most frequently used. Although the survival outcomes have been improved in recent years, still many patients have got disease relapses due to drug resistance. Therefore, There is an urgent need to know more about chemotherapy resistance and to create novel therapeutics and approaches. Nowadays, more attention is paid to the immune-oncology (IO) agents especially for tumors having PD-L1+ infiltrating immune cells. It would improve overall survival (OS) for re-clisponders presumably. Many other agents and combinations are currently investigated in laboratory and tested in clinics, where not only IO aspects and gene repair disorders but also epithelial mesenchymal transition (EMT), induction of stem-like cell phenotype, androgen receptor activation, altered nuclear acid metabolism and lipid metabolism are intensively studied. Furthermore, various antibody drug conjugate researches are also going on. In this review, we would like to focus upon the frontier of new therapeutics development for TNBC disease from biological aspects and clinical aspects. New translational research aspects would be involved as well.
KeywordsBreast cancer, triple negative, immuno-oncology, DNA repair, chemotherapy resistance, molecular target, epithelial mesenchymal transition, androgen receptor
Submission Deadline30 Sep 2020